dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Burtness, Barbara |
dc.contributor.author | Rischin, Danny |
dc.contributor.author | Greil, Richard |
dc.contributor.author | Soulières, Denis |
dc.contributor.author | Tahara, Makoto |
dc.contributor.author | de Castro Junior, Gilberto |
dc.contributor.author | Braña Garcia, Irene |
dc.contributor.author | Basté Rotllan, Neus |
dc.date.accessioned | 2022-08-11T06:09:03Z |
dc.date.available | 2022-08-11T06:09:03Z |
dc.date.issued | 2022-07-20 |
dc.identifier.citation | Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol. 2022 Jul 20;40(21):2321–32. |
dc.identifier.issn | 1527-7755 |
dc.identifier.uri | https://hdl.handle.net/11351/7984 |
dc.description | Quimioteràpia; Carcinoma de cèl·lules escamoses de cap i coll |
dc.description.sponsorship | Funding for this research was provided by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co Inc, Kenilworth, NJ. |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation.ispartofseries | Journal of Clinical Oncology;40(21) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Cap - Càncer - Tractament |
dc.subject | Coll - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Squamous Cell Carcinoma of Head and Neck |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1200/JCO.21.02198 |
dc.subject.decs | carcinoma de células escamosas de cabeza y cuello |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1200/JCO.21.02198 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Burtness B] Yale University School of Medicine and Yale Cancer Center, New Haven, USA. [Rischin D] Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia. [Greil R] Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria. [Soulières D] Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada. [Tahara M] National Cancer Center Hospital East, Kashiwa, Japan. [de Castro G Jr] Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil. [Brana I, Basté N] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 35333599 |
dc.identifier.wos | 000827762800006 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |